3 results
The study aims to limit the use of anthracyclines and to reduce the dose of ATRA. Another aim is to stratify treatment by risk group: standard risk - WBC <10 x 109/l : high risk - WBC >=10 x 109/l. Furthermore this study aims to…
The current study is a confirmatory, randomized, double-blind, placebo-controlled, Phase III clinical trial to assess the efficacy and safety of PRM-151 in patients with IPF with or without concurrent treatment with pirfenidone or nintedanib.
Study WA42294 is a Phase III open-label extension (OLE) study to assess the long-term safety, efficacy, and pharmacokinetics of PRM-151 in patients with IPF with or without concurrent treatment with pirfenidone or nintedanib. Patients with IPF who…